|
ARMCX3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62436730732907E-12 |
| Normal-vs-Stage2 |
3.606900E-04 |
| Normal-vs-Stage3 |
1.21520005169629E-09 |
| Normal-vs-Stage4 |
8.85490003543765E-09 |
| Stage1-vs-Stage2 |
5.245600E-01 |
| Stage1-vs-Stage3 |
3.816600E-01 |
| Stage1-vs-Stage4 |
8.285400E-01 |
| Stage2-vs-Stage3 |
9.930800E-01 |
| Stage2-vs-Stage4 |
6.848400E-01 |
| Stage3-vs-Stage4 |
5.879200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.6242562850266E-12 |
| Normal-vs-AfricanAmerican |
5.781300E-03 |
| Normal-vs-Asian |
2.73400000416757E-08 |
| Caucasian-vs-AfricanAmerican |
7.679800E-01 |
| Caucasian-vs-Asian |
9.452000E-01 |
| AfricanAmerican-vs-Asian |
8.420000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.08528766371319E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
1.226190E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.99200722162641E-16 |
| Normal-vs-Age(41-60Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(61-80Yrs) |
6.14060002845918E-09 |
| Normal-vs-Age(81-100Yrs) |
2.112200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.710800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.135850E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.259400E-03 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.810180E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.862310E-03 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.693700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.980340E-02 |
| Classical-VS-Follicular |
1.66420000002887E-06 |
| Classical-VS-Other |
4.091800E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
4.105800E-02 |
| Tall-VS-Other |
8.904800E-01 |
| Tall-VS-Normal |
9.40779999458741E-08 |
| Follicular-VS-Other |
5.259000E-01 |
| Follicular-VS-Normal |
8.045800E-04 |
| Other-VS-Normal |
2.104000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.10622663543836E-15 |
| Normal-vs-N1 |
3.4347000021917E-08 |
| N0-vs-N1 |
3.348000E-01 |
|
|
